Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure
Data From the CHARM Program and the Duke Databank
G. Michael Felker, MD, MHS, FACC*,*,
Larry A. Allen, MD*,
Stuart J. Pocock, PhD1,
,
Linda K. Shaw, MS*,
John J.V. McMurray, MD, FACC1,
,
Marc A. Pfeffer, MD, PhD, FACC1,
,
Karl Swedberg, MD, PhD, FACC1,||,
Duolao Wang, PhD
,
Salim Yusuf, DPhil, FACC1,¶,
Eric L. Michelson, MD, FACC2,#,
Christopher B. Granger, MD, FACC1,* for the CHARM Investigators
* Duke Clinical Research Institute, Durham, North Carolina
London School of Hygiene and Tropical Medicine, London, United Kingdom
University of Glasgow, Glasgow, United Kingdom
Brigham and Womens Hospital, Boston, Massachusetts
|| Department of Medicine, Sahlgrenska University Hospital/Östra, Göteburg, Sweden
¶ McMaster University, Hamilton, Ontario, Canada
# AstraZeneca LP, Wilmington, Delaware.

View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Outcomes by RDW Quintiles
Adjusted hazard ratios by quintile of red cell distribution width (RDW) for cardiovascular (CV) death or heart failure (HF) hospitalization in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) program (A), all-cause mortality in CHARM (B), and all-cause mortality in Duke Databank (C).
|
|
Copyright © 2007 by the American College of Cardiology Foundation.